Top

News & Events

News Archive: Client News

2014

18 December 2014
Imperial Innovations: Imperial College London, named as the UK’s top research university

18 December 2014
e-Therapeutics Reports Progress in ETS2101 Phase 1a and Oral Dosing Studies

17 December 2014
Xellia Pharmaceuticals Focuses on Innovation in Anti-infectives with Formation of Scientific Advisory Board

15 December 2014
NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology

11 December 2014
NetScientific Enters Into an Alliance with Healthbox to Invest in New Early-Stage Healthcare Companies

10 December 2014
Evaluate Ltd - Innovation Driving Positive Outlook for Pharma and Biotech in 2015

10 December 2014
Premaitha Health - Results for 7 months to 30 September 2014

10 December 2014
New Addition to NOXXON Supervisory Board Brings Significant US Public Market Expertise

08 December 2014
Direct biological production of Propylene – Third star on GLOBAL BIOENERGIES’ race to renewable olefins

08 December 2014
Prosensa Wins Scrip ‘Biotech Company of the Year’ 2014 Award

08 December 2014
Orphan Drug Status Granted to Telormedix's lead product Vesimune

08 December 2014
NetScientific Invests in Breakout Labs’ Portfolio Company EpiBone

05 December 2014
NOXXON Pharma: Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference

04 December 2014
GE Healthcare Life Sciences licenses CRISPR gene engineering technology patents from Broad Institute

04 December 2014
Forbion Announces Sale of Portfolio Company PneumRx to BTG for up to EUR 385M (USD 475M)

02 December 2014
Oxford Gene Technology Announces Operational and Financial Highlights for FY 2014

28 November 2014
Premaitha Health Wins Bionow Investment Deal of the Year Award

27 November 2014
e-Therapeutics: Research and Development presentation to Investors and Analysts

26 November 2014
Global Bioenergies Announces Break-through in Direct Biological Production of Butadiene

25 November 2014
Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform

25 November 2014
Nanobiotix secures financing from a major US investor, to address the US market

25 November 2014
Imperial Innovations leads GBP 50 million Series B funding round in Cell Medica

25 November 2014
Cell Medica Announces GBP 50 Million Series B Round

24 November 2014
BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa’s Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio

20 November 2014
Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus

18 November 2014
DNAe Highlights the Urgent Need for Fast Diagnostics to Help Tackle the Growing Threat of Antibiotic Resistance

18 November 2014
On European Antibiotic Awareness Day Xellia Pharmaceuticals Strengthens Commitment to Innovation in Anti-Infectives with New API R&D Center of Excellence in Oslo

17 November 2014
Global Bioenergies: Successful First Trial in its Industrial Pilot

17 November 2014
Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments

14 November 2014
Nanobiotix revenue for the 3rd quarter of 2014

14 November 2014
GE Healthcare Life Sciences to Open Biopharmaceutical Technology and Training Laboratory in Turkey

13 November 2014
Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels

12 November 2014
Oncoethix starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)

12 November 2014
Polyphor’s lead antibiotic POL7080 receives Qualified Infectious Disease Product (QIDP) designation from the FDA

10 November 2014
Prosensa Holding N.V. to Webcast Conference Call Discussing 3rd Quarter 2014 Financial Results and Corporate Update on November 17, 2014

10 November 2014
Histide Raises CHF 4.5 M (USD 4.6 M) Series A Investment Round to Advance Its Pioneering Recoding Therapeutics™ Technology

10 November 2014
Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium

06 November 2014
Premaitha Health Prepares for Launch of the IONA® test with Key Commercial Appointment

05 November 2014
New Sheriffs in Town: GE’s Crotonville Training Center welcomes Five Law Enforcement Leaders for Executive Education

04 November 2014
Professor Richard F. Neville and Mr Eric Chemla Join the Independent Vascular Flow Technologies’ Scientific Advisory Board

03 November 2014
Clinical Network Services (CNS) signs cooperative agreement with BD Consultancy

27 October 2014
Gallus BioPharmaceuticals and GE Healthcare Life Sciences win global bioprocessing industry award

27 October 2014
OGT Initiates Clinical Trial of New Array-Based Non-Invasive Prenatal Test (NIPT)

24 October 2014
GE Healthcare Life Sciences wins prestigious bioprocessing industry award

23 October 2014
Auspherix Secures Additional AU$1Million From MRCF to Advance its Antibiotic Pipeline

23 October 2014
Xellia Pharmaceuticals Welcomes HM the Queen of Denmark to Zagreb R&D Center of Excellence During State Visit to Croatia

21 October 2014
Karus Therapeutics Appoints New Head of Clinical Development and Head of Biology

21 October 2014
Liftstream Report Finds Ten Men for Every Woman Present in Biotech Boardrooms

20 October 2014
Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference

16 October 2014
Appointment of Executive Director

16 October 2014
Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe

15 October 2014
Imperial Innovations Group plc - Four IPOs, £150m raised and portfolio value up 38% to £252m

15 October 2014
Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infections

13 October 2014
Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers

10 October 2014
Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy

09 October 2014
OGT Named OBN’s Best Medtech Dealmaker

08 October 2014
PharmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific

07 October 2014
NovaBiotics’ Dr Deborah O’Neil Named EY UK Health Products & Services Entrepreneur of 2014

07 October 2014
Atopix Therapeutics Secures Funding from SR One to Advance Development of CRTH2 Antagonists in Eosinophilic Disease

06 October 2014
Medtech Market to Achieve Global Sales of $514 Billion by 2020; Megamergers Set to Reshuffle Top Players

03 October 2014
Gallus BioPharmaceuticals and GE Healthcare Life Sciences named as finalists for global bioprocessing industry award

03 October 2014
Promosome and GE Healthcare Life Sciences nominated for global bioprocessing industry award

03 October 2014
GE Healthcare Life Sciences named as finalist for four bioprocess industry awards

03 October 2014
Forbion Capital Partners Announces First Close of FCF III

03 October 2014
NetScientific’s subsidiary, Glycotest Begins a New Research Collaboration with Oncimmune

02 October 2014
Ability of Semiconductor DNA Sequencing to Transform Healthcare and Save Lives Recognised by the 2014 Faraday Medal to Professor Chris Toumazou

30 September 2014
Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum

30 September 2014
ADC Therapeutics Expands Team

29 September 2014
Clinigen Group plc Receives FDA’s First Ever Drug Shortage Assistance Award

26 September 2014
Prosensa extends the re-dosing of drisapersen in Europe in patients with Duchenne muscular dystrophy

26 September 2014
Cell Reports Publication on the Mechanism of Action of NOXXON’s Anti-SDF-1 Spiegelmer® Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models

24 September 2014
Prosensa publishes a sensitive, reproducible and objective methodology for dystrophin analysis in patients with Duchenne muscular dystrophy

24 September 2014
Cell Medica announces the appointment of Andrea Ponti as Non-Executive Director

24 September 2014
DNAe Completes its Leadership Team with Key Operational and R&D Appointments as it Takes Forward its DNA Diagnostic Test for Sepsis

24 September 2014
Clinigen Full Year Results - Underlying EBITDA up 19.8% and EPS up 22%

22 September 2014
Telormedix granted European Patent for Vesimune

22 September 2014
Clinical Network Services (CNS) and Ventac Partners sign cooperative partnership

22 September 2014
Nanobiotix expands operations into the USA as part of its international development strategy

19 September 2014
AmpliPhi Announces Departure of CEO

18 September 2014
Clinigen Group launches New First-in-Class Antibiotic VIBATIV® (telavancin) for MRSA related Hospital-Acquired Pneumonia across Europe

18 September 2014
Biotech Venture Capital Firm Aglaia Launches New $65 Million

18 September 2014
NOXXON Pharma Expands Management Team by Appointing

17 September 2014
Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy

16 September 2014
NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® for the Treatment of Cystic Fibrosis

16 September 2014
e- Therapeutics Half Yearly Results

16 September 2014
Vaxxas Initiates Research Project on Advancing Next Generation Technology for Polio Vaccine Delivery

15 September 2014
Xellia Pharmaceuticals Seeks New Talent as it Expands

09 September 2014
Prosensa announces 12 presentations at the 19th International Congress of the World Muscle Society in Berlin

08 September 2014
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy

04 September 2014
Two Presentations at International Conferences of Preclinical Data on NOXXON’s anti-C5a Spiegelmer®, a Potential Drug in Pneumococcal Pneumonia-Induced Sepsis

04 September 2014
Source BioScience: Appointment to the Board

04 September 2014
Clinigen Group: Notification of Full Year Results Date

03 September 2014
Cerenis receives EMA Orphan Drug Designations for CER-001 for the treatment of ApoA-I and ABCA-1 deficiencies

29 August 2014
Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia

29 August 2014
Nanobiotix Half Year Results for the six months ended 30 June 2014

26 August 2014
Vaxxas Selected as World Economic Forum Technology Pioneer 2015

20 August 2014
Mood Lifts for Medtech in First Half of 2014 While Pharma Sector Faces New Struggles

20 August 2014
Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol® (amifostine), from AstraZeneca

20 August 2014
Source BioScience Half Year Report for the Six Months Ended 30 June 2014

13 August 2014
Novogen Announces Results of General Meeting of Shareholders

12 August 2014
Novogen Receives Funding Support to Commence Studies in Muscular Dystrophy

11 August 2014
Prosensa and CureDuchenne Strengthen Long-term Collaboration with an Additional €5M to Advance DMD Pipeline

07 August 2014
New ISPE White Paper Provides Guidance on Development and Implementation of Regulatory-Compliant Patient Access Programs

05 August 2014
Forbion Announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m

05 August 2014
Seventure’s Portfolio Company Santaris Pharma Sold for Up To US $450m to Roche

04 August 2014
Prosensa Holding N.V. to Webcast Conference Call Discussing 2nd Quarter 2014 Financial Results and Corporate Update on August 12, 2014

04 August 2014
BioGasol Establishes Licensed Carbofrac® Reactor Manufacture by Sweetwater Energy

31 July 2014
NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia

25 July 2014
Novogen and CanTx Appoint Contract Manufacturers to Produce Clinical Batches of Cantrixil™

25 July 2014
Year End Trading Update

21 July 2014
HealthUnlocked, Europe’s Largest Social Network for Health, Expands to the US

21 July 2014
OGT Awarded £200K Contract by SBRI to Develop Innovative Whole Genome NGS Analysis Software

09 July 2014
Forbion Announces Closing of Initial Public Offering of Portfolio Company arGEN-X

09 July 2014
Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995

07 July 2014
Xellia Pharmaceuticals Expands into the US with Acquisition of Manufacturing Plant

07 July 2014
Lesaffre Invests €10m into Seventure’s Health for Life Capital Fund Investment

04 July 2014
Premaitha Looks to Deliver Diagnostic Test Product to Improve Prenatal Screening Globally

03 July 2014
Source BioScience - Appointment to the Board

02 July 2014
Nordic Life Science Days 2014, Stockholm 7-9 September

01 July 2014
Stage 3 Phase 2 Study of DARPin Abicipar Pegol (previously MP0112) Supports Progressing to Phase III Development Program

30 June 2014
Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments

27 June 2014
Prosensa Awarded $200,000 Research Grant from PPMD

27 June 2014
NovaBiotics’ Dr Deborah O’Neil Wins Entrepreneur of the Year

25 June 2014
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy

25 June 2014
Initiation of a Phase IIa Clinical Study for Lynovex® in Cystic Fibrosis

25 June 2014
First successful exit in 2014 for Seventure Partners

24 June 2014
Evaluate Ltd: Worldwide Prescription Drug Sales to Exceed Trillion Dollar Mark by 2020

24 June 2014
Marks & Clerk: US Organisations Reaping Rewards of Public Investment in Genomic Research, with Europe and Asia Lagging Behind

23 June 2014
CytoTools AG Adds Cardiovascular and Further Indications to Its Field of Interest Following Capital Increase at CytoTools Subsidiary CytoPharma GmbH

20 June 2014
Clinigen Group’s Peter George Wins Chief Executive of the Year Award

20 June 2014
NovaBiotics’ Dr Deborah O’Neil Named EY Scotland Entrepreneur of 2014

18 June 2014
Big Pharma Becomes a Smaller Employer While Biotech Booms

17 June 2014
Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells

16 June 2014
Portfolio company Abzena announces intention to float

13 June 2014
NOXXON Presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients

12 June 2014
Source BioScience plc: Annual General Meeting Statement

04 June 2014
Autifony Therapeutics Awarded £2.2 million to Progress First-In-Class Drug for Tinnitus into Phase IIa Study

04 June 2014
Imperial Innovations Group plc: Autifony Receives Funding from Technology Strategy Board for Phase II Clinical Trial in Tinnitus

03 June 2014
Prosensa Announces Regulatory Path Forward for Drisapersen as a Potential Treatment for DMD

02 June 2014
NOXXON’s Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference

02 June 2014
Nanobiotix Presents Successful Phase I Results for its Lead Nanomedicine Product NBTXR3 at ASCO

02 June 2014
Imperial Innovations plc: Peter Chambré and Linda Wilding Appointed as Non-Executive Directors

02 June 2014
Imperial Innovations Group plc: Proposed Placing to Raise Up to £150 million

02 June 2014
Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS

27 May 2014
Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer

27 May 2014
Auven Therapeutics and BELLUS Health Announce Completion or Enrollment in the Phase III Confirmatory Study of KIACTA™ for the Treatment of AA Amyloidosis

20 May 2014
Prosensa Announces 1st Quarter 2014 Financial Results and Recent Corporate Developments

19 May 2014
Source BioScience - Interim Management Statement

19 May 2014
ADC Therapeutics to Move ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

16 May 2014
Telormedix’s Vesimune Successfully Completes Phase II for Carcinoma In Situ of the Bladder

14 May 2014
Xellia Pharmaceuticals Expands Croatian Product and Innovation R&D Centre of Excellence with Investment of US$2.0 million

13 May 2014
BioSpring Selects GE Healthcare Life Sciences OligoProcess™ for Large Scale Synthesis of Therapeutic Oligonucleotides

12 May 2014
Nanobiotix Revenue for the 1st Quarter of 2014 and new composition of the shareholding

12 May 2014
e-Therapeutics’ full year results for the 12 months ended 31 January 2014

08 May 2014
e-Therapeutics Announces Recruitment Resumes into US phase I ETS2101 Brain Cancer Trial

08 May 2014
Scil Proteins Announces New Management Team and Revised Focus

07 May 2014
Auven Therapeutics and Bellus Health Announce Engagement of Financial Advisor to Explore Sale of KIACTA™, an Experimental Drug in Phase III Development for the Treatment of AA Amyloidosis

07 May 2014
Apitope Initiates Preclinical Development of Peptide Therapy,ATX-F8-117, to Treat Factor VIII Intolerance

07 May 2014
Pantec Biosolutions Announces Research Agreement with Takeda to Investigate New Approaches for Inflammatory Skin Disease

06 May 2014
Novogen: Children’s Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood Cancers

05 May 2014
Novogen Presentation at Cavendish Global Impact Forum Available Online

02 May 2014
Auven Therapeutics and BELLUS Health Announce Licence Agreement with Mount Sinai for KIACTATM in Sarcoidosis

02 May 2014
Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases

01 May 2014
Fibrotech acquired by Shire for US$75M plus milestones

01 May 2014
Sovaldi Forecast to be Biggest Selling Drug in 2020 as EvaluatePharma Extends Consensus Sales Forecasts

01 May 2014
Prosensa Provides Update on Drisapersen

28 April 2014
Seventure Partners’ Health for Life Capital Fund Makes First Investments

28 April 2014
GE Healthcare Life Sciences and Promosome sign licensing agreement

25 April 2014
e-Therapeutics plc (AIM: ETX) Notification of Full Year Results Date

23 April 2014
NovaBiotics Shortlisted for the Grampian Award for Innovation

14 April 2014
Clinigen Group to Manage International Named Patient Program for Abiogen Pharma’s Nerixia® (Neridronic Acid)

12 April 2014
Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session

08 April 2014
Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study

08 April 2014
Prosensa to Appoint Michael Wyzga to Supervisory Board

07 April 2014
e-Therapeutics Announces That Steve Medlicott Has Been Appointed Finance Director

07 April 2014
e-Therapeutics Announces Directorate Change

04 April 2014
NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study

02 April 2014
Synthon’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC

01 April 2014
Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

01 April 2014
Source BioScience Launches its Products and Services in the USA – Facilities in Los Angeles and Atlanta

31 March 2014
Hookipa Biotech Wins Best Financing Deal Award in the Vaccine Industry Excellence (ViE) Awards 2014

31 March 2014
e-Therapeutics Reports Positive Interim Results From UK Phase Ia Trial of ETS2101 (Dexanabinol) in a Variety of Solid Tumours

31 March 2014
Clinigen Group Acquires Oncology Support Therapy SAVENE® (dexrazoxane) from SpePharm AG

28 March 2014
Circassia IPO drives jump in profits as portfolio matures

27 March 2014
Synthon Announces Successful Outcome of the Phase III GATE Study with its generic Glatiramer Acetate

26 March 2014
e-Therapeutics Announces Recruitment Resumes into UK Phase I ETS2101 Cancer Trial

25 March 2014
Global Bioenergies: Key Patents Granted in First Country

18 March 2014
Prosensa Announces Full Year 2013 Financial Results and Recent Corporate Developments

18 March 2014
Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo

18 March 2014
Preliminary Results for the Year Ended 31 December 2013

18 March 2014
Clinigen Group Reports Pan European Lifting of Marketing Authorization Suspension for VIBATIV® (telavancin)

17 March 2014
Prosensa Announces 48-Week Data from a U.S. Phase II Placebo-Controlled Study of Drisapersen in 51 DMD Boys

12 March 2014
Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York

12 March 2014
Spectacular Images Showing Research into Cancer, Neurodegenerative Disease and Fertility Win GE Healthcare 2013 Cell Imaging Competition

11 March 2014
Novogen Selected to Present at Cavendish Global Health Impact Forum

11 March 2014
M&A Slowdown and Drop in FDA Approvals Stifles Growth of Medtech Sector in 2013

11 March 2014
Evaluate Ltd: Record-Breaking Valuations and Surging Share Prices Drive Strong Pharma and Biotech Sector Performance in 2013

10 March 2014
Fibrotech Announces Positive Phase Ia Results for Anti-fibrotic FT011

10 March 2014
Clinical Network Services (CNS) Opens New UK Office and Expands Core Services

04 March 2014
Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence

04 March 2014
OGT Expands Leadership in Genomic Medicine with Acquisition of Cytocell Ltd

03 March 2014
Fibrotech is Granted US and Canadian Patents for its Anti-fibrotic Compounds

26 February 2014
Clinigen Group plc Announces Half Year Results for the Six Months Ended 31 December 2013

24 February 2014
Cancer Therapeutics Cooperative Research Centre (CTx) Successful in Application for Further Funding

20 February 2014
Forbion Announces Closing of Public Offering of Portfolio Company, Argos Therapeutics

18 February 2014
SynAffix Raises Series A Investment Round to Advance its GlycoConnect™ Technology for Creating Next-Generation ADCs

17 February 2014
Stroke Patients With Swallowing Problems Show Improved Recovery With New Treatment, Study Shows

13 February 2014
Forbion Announces Closing of Initial Public Offering of Portfolio Company uniQure

10 February 2014
e-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers

07 February 2014
NovaBiotics Wins Life Science Business Leadership Award

06 February 2014
Circassia announces intention to float

05 February 2014
Evaluate Ltd: Absence of Blockbuster Drug Launches in 2014 Puts R&D Productivity at Risk

03 February 2014
Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform

24 January 2014
e-Therapeutics announces temporary halt of recruitment into ETS2101 cancer trials because of drug supply issue

22 January 2014
Nanotherapeutics selects GE Healthcare Life Sciences technologies for Advanced Development and Manufacturing Center

21 January 2014
GLOBAL BIOENERGIES partners with AUDI on drop-in biofuel

20 January 2014
Seventure Partners Launches New €120m ‘Health For Life Capital’ Innovation Fund

20 January 2014
Imugene Appoints Distinguished Scientists to Scientific Advisory Board

16 January 2014
Prosensa Reports Initial Findings from the Further Clinical Data Analyses of Drisapersen for the Treatment of Duchenne Muscular Dystrophy

14 January 2014
Clinigen Group Extends Exclusive Agreement with Accord Healthcare to Supply Anti-Cancer Drug Capecitabine into Clinical Trials in Europe

13 January 2014
Prosensa Regains Rights to Drisapersen from GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD)

13 January 2014
Dezima Pharma Completes Patient Enrolment for TULIP Phase 2b Study with CETP Inhibitor TA-8995

09 January 2014
ARAVIS Strengthens Life Science Team with Three Important Appointments

08 January 2014
Apitope Led Consortium Receives up to €6M FP7 Funding to Develop Novel Therapeutic Vaccine for Graves’ Disease

08 January 2014
Clinigen Group to Provide VIBATIV® to Patients with Hospital-Acquired Bacterial Pneumonia in Europe via Access Program

07 January 2014
DySIS Medical Appoints Robert Cascella as Chairman

07 January 2014
e-Therapeutics Provides Update on ETS2101 Phase I Trial in Brain Cancer

07 January 2014
Nanobiotix 2013 Review: Significant Corporate and Clinical Progress

07 January 2014
Cell Medica Announces Orphan Drug Designation in the European Union for Cytovir ADV

07 January 2014
Imperial Innovations Group plc: Portfolio Company Cell Medica Announces Orphan Drug Designation in the European Union for Cytovir ADV

06 January 2014
GE to Expand in Life Sciences with Acquisition of Strategic Assets from Thermo Fisher Scientific

2013

30 December 2013
Imperial Innovations makes further investment in TopiVert

20 December 2013
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer

18 December 2013
Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients

18 December 2013
Imperial Innovations partners with Jetstream Capital for £5.1m funding round

17 December 2013
NovaBiotics Initiates Development of Orphan Drug in Cystic Fibrosis

17 December 2013
Imperial Innovations Group plc Leads £17.5m Funding Round for Crescendo Biologics

16 December 2013
AmpliPhi Biosciences Announces $18 Million Private Placement

09 December 2013
NOXXON Pharma: Interim Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in CLL and MM Studies

06 December 2013
Nanobiotix strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar

04 December 2013
GE Healthcare Scientist Paired with Welsh MP to Share Insights on Science and Policy-Making

04 December 2013
Roche and Molecular Partners enter into alliance to develop new cancer treatments

03 December 2013
MRCF Invests AU$1m in Antibiotics Start-Up Auspherix

02 December 2013
JHL Biotech Selects GE’s FlexFactory™ Biomanufacturing Platform for Taiwan Facility

02 December 2013
Telormedix Raises CHF 6 M ($ 6.6 M) in Series B Financing Round

26 November 2013
Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology

26 November 2013
Novogen Announces That CanTx Drug Destroys Ovarian Cancer Stem Cell Spheroids

25 November 2013
Prosensa and Partners Awarded Second European Consortium FP7 Research Grant

22 November 2013
Oxford Immunotec trading commences on NASDAQ

20 November 2013
Dr Nigel Ramsden joins SYNthesis med chem as Head of European Operations

19 November 2013
Atopix Therapeutics Recruits First Patient in Phase 2 Trial of OC459 for Atopic Dermatitis

19 November 2013
Source BioScience plc: Interim Management Statement

18 November 2013
Prosensa Announces Third Quarter 2013 Financial Results and Recent Corporate Developments

18 November 2013
MISSION Therapeutics Secures £20 Million ($32 Million) in Series B Financing to Drive Development of Ubiquitin Pathway Inhibitors

18 November 2013
Imperial Innovations Group plc: MISSION Therapeutics receives £20m Series B funding

15 November 2013
Prosensa Awarded Best SME Biotech Pipeline 2013 at the Rare & Orphan Advocacy and Research (ROAR) Awards

14 November 2013
Novogen Announces Important Discovery in Program to Develop Drugs Against Genetic and Degenerative Disorders

14 November 2013
Toumaz: UK Patient Safety to be Boosted by Wireless Vital Signs Monitor

13 November 2013
2013 FDA Approval Rates Suggest Record Year for Post-Launch Success

12 November 2013
GE Healthcare Life Sciences Launches Xuri™ Technology Family for Cell Therapy Manufacturing

12 November 2013
Scil Proteins Production to Join WACKER Creating Leading Microbial-based Biopharmaceutical Manufacturer

12 November 2013
Karus Therapeutics Appoints Penelope Ward as CMO

08 November 2013
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

07 November 2013
Prosensa Enrolls 100th Patient to its Natural History Study of Duchenne Muscular Dystrophy

05 November 2013
ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology

04 November 2013
Polyphor and Roche Join Efforts to Combat Multidrug-Resistant Bacterial Infections

04 November 2013
Hookipa Biotech Closes €20 Million ($27.5 Million) in Series B Financing

31 October 2013
Scil Proteins and LEUKOCARE: Novel Recombinant Human Thrombin Provided in Innovative Stabilized Formulation

31 October 2013
Protego Launched with Start-up Investment from the MRCF to Develop Sternal Device for Cardiac Surgery

31 October 2013
e-Therapeutics starts phase IIb trial of ETS6103 in major depressive disorder

30 October 2013
NovaBiotics’ Lynovex® Gains Support From The UK’s Cystic Fibrosis Trust

21 October 2013
Accentus Medical: Agluna® Treated Devices Significantly Reduce Infection Rates

21 October 2013
OGT strengthens focus on cancer biomarkers

17 October 2013
AmpliPhi Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies Targeting C. Difficile

16 October 2013
Imperial Innovations Group plc: Nigel Pitchford and Tony Hickson Appointed Directors

16 October 2013
Imperial Innovations Group plc: Oxford Immunotec makes public S-1 filing for potential IPO on NASDAQ

16 October 2013
Imperial Innovations Group plc: Full Year Results

16 October 2013
e-Therapeutics’ interim results for the six months ended 31 July 2013

15 October 2013
Auven Therapeutics Announces AstraZeneca’s MedImmune Acquires Antibody-Drug Conjugate Company Spirogen and Invests in ADC Therapeutics

14 October 2013
BioInvent and Bayer Extend and Broaden Collaboration for the Discovery and Development of Therapeutic Antibodies

03 October 2013
TranScrip Partners Announce Hong Kong Expansion

02 October 2013
Karus Therapeutics wins ‘Best Biotech Fundraiser’ award

01 October 2013
Imperial Innovations Group plc: Circassia’s Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season

01 October 2013
Xenios and LEUKOCARE Announce Strategic Partnership in the Field of Anti-Inflammatory Coatings for Next Generation Extracorporeal Support Systems

25 September 2013
GE Healthcare Life Sciences to build KUBio modular biopharmaceutical factory for JHL Biotech in China

25 September 2013
Clinigen Group plc: Preliminary Results for the year ended 30 June 2013

23 September 2013
Imperial Innovations Group plc: Portfolio Company IXICO Expands into Digital Healthcare

23 September 2013
Accentus Medical Announces Completion of Management Buyout

23 September 2013
Nanobiotix Strengthens Its Management Team

19 September 2013
Evaluate: Fall in Licensing Deals Characterizes First Half of 2013 in the Pharmaceutical Sector

17 September 2013
Source BioScience plc: Recommended Cash Offer for Vindon Healthcare plc - Offer Declared Unconditional in All Respects

16 September 2013
Clinigen Group on Track with European Marketing Authorization Transfers for Cardioxane and VIBATIV

12 September 2013
Source BioScience: Recommended Cash Offer For Vindon Healthcare plc - Offer Declared Unconditonal As To Acceptances

10 September 2013
MedTech Sector Stalled by Significant Drop in FDA Approvals, M&A Slowdown

10 September 2013
Imperial Innovations leads £8m series ‘C’ funding round in Plaxica

09 September 2013
SYNthesis Med Chem Opens New Facility in Cambridge, UK

09 September 2013
Clinigen Group Selected to Manage Access Program by Eisai for Fycompa (perampanel) in Germany

06 September 2013
Prosensa Initiates First Patient Dosing in Phase I/II trial of PRO053

06 September 2013
Nexus6 Steps Up its Global Presence with Three New Appointments

06 September 2013
Clinigen Group plc - Notification of Full Year Results Date

06 September 2013
Clinigen Group plc - Appointment of Peel Hunt as Joint Broker

04 September 2013
Mind-NRG Successfully Completes 6 Million Euro Series B Financing

03 September 2013
LEUKOCARE announces EUR 3.4 M capital increase

03 September 2013
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis

03 September 2013
TranScrip Partners Announce Australian/Asian Appointment

02 September 2013
Nanobiotix Half Year Results for the period ended 30 June 2013

30 August 2013
New number of shares and votes in BioInvent International AB (publ)

29 August 2013
Source Bioscience plc Recommended Cash Offer for Vindon Healthcare plc - First Closing Date Announcement

29 August 2013
Dezima Pharma Initiates Phase 2b TULIP Study on CETP Inhibitor Program DEZ-001

29 August 2013
Source BioScience plc: Half Year Report for the Six Months Ended 30 June 2013

28 August 2013
NovaBiotics Enters into Agreement with Taro

28 August 2013
Prosensa Announces Second Quarter 2013 Financial Results and Recent Corporate Developments

23 August 2013
Source BioScience plc - Result of Open Offer

23 August 2013
Source BioScience plc - Result of General Meeting

21 August 2013
Karus Therapeutics Secures Prominent Role in Epigenetics Debate at SciBX Summit 2013

20 August 2013
Prosensa Holding N.V. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on August 28, 2013

19 August 2013
GE Healthcare Life Sciences, Osaka University Team Up to Develop Future Leaders of Japan’s Life Sciences Sector

12 August 2013
caprotec bioanalytics and Syngenta announce research collaboration

08 August 2013
AmpliPhi Presents Data on Bacteriophages in the Treatment of Lung Infections in Cystic Fibrosis

07 August 2013
Source BioScience plc: Recommended Cash Offer for Vindon Healthcare

07 August 2013
Source BioScience plc: Announcement of Open Offer to Raise up to Approximately £1 million Before Expenses through the Issue of up to 10,778,066 New Ordinary Shares

07 August 2013
Telormedix Receives EU Funding for the Development of a New Treatment for Psoriasis

07 August 2013
gIcare Pharma Initiates Phase 2a Study of its Lead Product, GIC-1001, in Sedation-Free Analgesia for Colorectal Cancer Screening

06 August 2013
Prosensa to Present at Wedbush 2013 Life Sciences Management Access Conference

01 August 2013
Source BioScience plc Possible Recommended Offer for Vindon Healthcare PLC (“Vindon”)

31 July 2013
Prosensa Awarded EUR 6 million EU FP7 Research Grant

31 July 2013
Polyphor Achieves First Milestone in Macrocycle Drug Discovery Collaboration with Boehringer Ingelheim

31 July 2013
Clinigen Group to Manage Third Access Program for BTG

26 July 2013
Imperial Innovations' Portfolio Company PolyTherics Merges with Antitope

25 July 2013
Clinigen Group plc: Pre-Close Trading Update

25 July 2013
Eurofins Panlabs strengthens drug discovery services with GE Healthcare’s Cytiva Cardiomyocytes

25 July 2013
BioInvent Interim Report

24 July 2013
Source BioScience issues update regarding funding arrangements for the possible offer for Vindon Healthcare PLC

24 July 2013
NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy

22 July 2013
caprotec bioanalytics and Bayer CropScience Announce Second Collaborative Research Agreement

17 July 2013
Imperial Innovations Group plc: Board Change

16 July 2013
Source BioScience plc: Possible Offer for Vindon Healthcare plc

15 July 2013
ADC Therapeutics Licenses Proprietary Antibody from BZL Biologics for Prostate Cancer

09 July 2013
Clinigen Group Makes Organizational Changes to Scale-up for Future Business Growth

08 July 2013
Prosensa Holding N.V. Announces Closing of Initial Pubilc Offering

08 July 2013
BioInvent Receives Clinical Milestone in Partner Program

08 July 2013
OncoEthix Closes 18 Million CHF (~US$19 Million) Series B Financing

03 July 2013
Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication

02 July 2013
Imperial Innovations Group plc: £30m, 12-year loan to Imperial Innovations from European Investment Bank for healthcare investment

02 July 2013
BioInvent extends collaboration for the discovery and development of therapeutic antibodies with Mitsubishi Tanabe

01 July 2013
AmpliPhi Signs Global R&D Agreement with US Army to Develop Bacteriophage Therapies to Treat Resistant Bacterial Infections

01 July 2013
Autifony Therapeutics Announces £2.75m Collaboration with Universities of Manchester and Newcastle to Progress a First-in-Class Drug for Schizophrenia

28 June 2013
Prosensa Holding B.V. Prices Initial Public Offering

26 June 2013
Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the National Cancer Institute for development

25 June 2013
Imperial Innovations Group: Investment in Psychology Online

24 June 2013
VivaMab and ADC Therapeutics Announce Antibody Licensing Deal for Novel ADC Candidate to Target Hematologic Cancers

24 June 2013
Evaluate Group Report Return to Growth for Pharmaceutical Sector: Surge in Drug Approvals, R&D Productivity and Investor Confidence to Drive Expansion Through 2018

20 June 2013
Prof Marc Van Montagu, Chairman of FuturaGene’s Scientific Advisory Board, Receives the World Food Prize 2013

20 June 2013
Clinigen Group Extends Agreement to Exclusively Supply Clinical Trials with Accord Healthcare’s EU Oncology Products

17 June 2013
Source BioScience launches new Overnight Service for DNA sequencing for Scotland

17 June 2013
Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD Warhead

13 June 2013
Evaluate Report to Examine Life After the Patent Cliff, Provides Analysis on Pharmaceutical and Biotech Markets and Consensus Forecasts to 2018

13 June 2013
Digital Health Poised to Change the Face of Healthcare

13 June 2013
Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3

12 June 2013
Dezima Pharma Appoints Seasoned New CEO

11 June 2013
Polyphor Attracts Senior Pharma Professionals to Strengthen its Board of Directors

10 June 2013
Digital Health Forum 2013 (DHF13) Announces its Top Speaker Line-up

04 June 2013
Autifony Therapeutics Initiates Phase I Study for Lead Product, AUT00063, for the Treatment of Hearing Loss and Tinnitus and Tops Up Series A Financing with Further £5.5 million Investment

04 June 2013
OGT Launches Pre-implantation Genetic Screening Array Aimed at Improving the Chances of Successful IVF

04 June 2013
Imperial Innovations: Autifony Initiates Phase I Trial for Treatment of Hearing Loss and Tinnitus

03 June 2013
Ockham Biotech Overturns Vectura's Challenge to Secure European Patent Rights for Inhaled Heparin in the Treatment of COPD

03 June 2013
Nanobiotix’s NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma

30 May 2013
Uscom to Acquire New Zealand-based Pulsecor and New Blood Pressure Products

29 May 2013
Atopix Therapeutics awarded Biomedical Catalyst grant to study an innovative anti-allergic approach to the treatment of atopic dermatitis

29 May 2013
FuturaGene enters agreement with Danforth Center to provide plant yield-enhancing technology to developing countries

28 May 2013
OGT launches ground-breaking 58-gene tumour profiling service to predict patient response to cancer treatment

28 May 2013
ugichem receives €2.25 million funding for antisense drug platform

24 May 2013
BioInvent Recruits Michael Oredsson As New CEO

22 May 2013
Phagenesis Expands Series B Financing to $17 million

21 May 2013
Novo A/S acquires Xellia Pharmaceuticals for US$ 700 million

21 May 2013
Competition Launched to Select the Hottest Five Emerging Companies in the Digital Health Space

16 May 2013
Source BioScience Interim Management Statement

15 May 2013
Nanobiotix revenue for the 1st quarter of 2013

14 May 2013
e-Therapeutics’ Preliminary Results for the Year Ended 31 January 2013

10 May 2013
OGT Marks World Lupus Day with Announcement of Novel Biomarker Panel to Support Earlier SLE Diagnosis

08 May 2013
Cell Medica Announces Treatment of First Pediatric Patient in Early Stage Clinical Trial of Cytovir ADV

08 May 2013
Sydney Based Cellmid Acquires Japanese Advangen

08 May 2013
Imperial Innovations Group plc: Cell Medica Treats First Paediatric Patient in Clinical Trial of Cytovir ADV

30 April 2013
Source BioScience plc: Acquisition of Inverclyde Biologicals Limited

25 April 2013
Nanobiotix 2012 Annual Results

25 April 2013
SensiumVitals® Pilot Study Demonstrates Significant Improved Patient Care and Hospital Cost Savings

23 April 2013
Digital Health Forum 2013 (DHF13), Royal Society of Medicine, London, UK, 11 June 2013

18 April 2013
BioGasol ApS Delivers its First Commercial Pretreatment System to Sweetwater Energy

18 April 2013
Forbion Capital Partners co-leads €15 Million Series A Financing for Allecra Therapeutics

16 April 2013
AmpliPhi Establishes Collaboration with Intrexon

15 April 2013
Recruitment in World's Largest Interventional Oncology Study Completed

15 April 2013
DySIS Medical receives £7.4m of additional funding

12 April 2013
Mesoblast Chief Executive Honoured at the Vatican with Inaugural Pontifical Award for Innovation

09 April 2013
Karus Therapeutics Appoints Scientific Advisory Board and Announces Move to New Oxford Facilities

08 April 2013
Spirogen and BioAtla present positive data on next-generation warheads in ADCs against cancer

08 April 2013
MISSION Co-Founder and CSO becomes an Associate Faculty Member at the Wellcome Trust Sanger Institute

04 April 2013
BioInvent Presents Positive Data for BI-505 at International Myeloma Congress

03 April 2013
Dr. Laurent Levy, CEO of Nanobiotix, receives the UB Entrepreneurship Award from the University at Buffalo, SUNY

26 March 2013
Clinigen Group plc acquires oncology support therapy Cardioxane® from a world-leading pharmaceutical company

22 March 2013
Imperial Innovations HY results - Major growth potential in key portfolio companies

21 March 2013
Dr Oern Stuge Appointed Chairman of Phagenesis

19 March 2013
Source BioScience Preliminary Results for Year Ended 31 December 2012

19 March 2013
Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference

18 March 2013
Biotechnology Business Leader Appointed CEO of Australian Nobel Prize Winner’s Company

18 March 2013
Vaxxas Recognized as 2013 BioSpectrum Asia-Pacific Emerging Company of the Year

14 March 2013
Mesoblast Completes A$170m Private Placement

13 March 2013
OGT granted licence by The Institute of Cancer Research, London, to develop and commercialise prostate cancer biomarker panel

11 March 2013
Celtic Therapeutics Rebrands as Auven Therapeutics

11 March 2013
Telormedix enrols first patient for Phase II in bladder cancer

11 March 2013
Clinigen and Theravance Announce Exclusive Commercialization Agreement in the EU for VIBATIV® (telavancin)

04 March 2013
Polyphor reports successful Phase I results for its Pseudomonas selective antibiotic POL7080

04 March 2013
Clinical Network Services (CNS) appoints leading toxicologist Douglas Francis to BioDesk

28 February 2013
Dezima Pharma raises €14.2m ($18.6m) to develop its CETP inhibitor program DEZ-001

27 February 2013
Winners of GE Healthcare 2012 Cell Imaging Competition announced

27 February 2013
Prosensa Receives Rare Disease Company Award from EURORDIS

27 February 2013
MISSION Therapeutics announces Biomedical Catalyst Feasibility award to tackle drug-resistant ovarian cancer

27 February 2013
Clinigen Group plc Announces Interim Results for the Six Months Ended 31 December 2012

26 February 2013
OGT Expands Commitment to Improved Cancer Profiling with CCMC Agreement

26 February 2013
Xellia Enters 4 Year Collaboration to Develop New Antibiotics to Combat Multi-Drug Resistant Bacteria

26 February 2013
York Teaching Hospital Signs Up BD FocalPoint™ and Renews £1.3m Cervical Cancer Screening Contract

25 February 2013
Ablynx and Spirogen enter into a research collaboration to evaluate the potential of novel toxin-nanobody drug conjugates in cancer

25 February 2013
Imperial Innovations Group plc - Circassia’s cat allergy treatment shows sustained symptom improvement

22 February 2013
Lab21 and IntegraGen partner to develop new colorectal cancer diagnostic

21 February 2013
BioInvent Financial Statement – 1 January to 31 December 2012

20 February 2013
Promising pre-clinical data in Cystic Fibrosis for ProtAffin AG’s PA401 to be presented at ATS, Philadelphia, 17-22 May 2013

19 February 2013
PolyActiva Raises AUD$9.2M in Series B Venture Funding

14 February 2013
Helmedix Launched with Start-up Investment from the MRCF to Develop Potential Treatment for Autoimmune Disease

13 February 2013
FDA Agreement on Mesoblast’s Use of Singapore Manufacturing Facility for Clinical Trial Production of Proprietary Mesenchymal Precursor Cells

13 February 2013
Nanobiotix Appoints Dr. Alain Herrera to the Supervisory Board

12 February 2013
Mireven Announces Positive In Vitro Results for miRNA-7-5p in Melanoma

11 February 2013
e-Therapeutics to Raise £40 Million to Advance Lead Cancer Drug and Exploit Network Pharmacology Platform

11 February 2013
Mesoblast Reports Half-Year 2013 Financial Results

07 February 2013
Larry Bell, MD Joins Prosensa as Head of Global Regulatory Affairs

07 February 2013
Celtic Pharma Welcomes the Results of the Sale Process of Inspiration Biopharmaceutical’s Hemophilia Assets to Cangene Corporation

07 February 2013
Key Mesenchymal Precursor Cell Patents Granted in United States and China

04 February 2013
AmpliPhi Receives Notice of Allowance on Key Patent for its Bacteriophage Therapy to Treat Drug-resistant Biofilm-based Infections

31 January 2013
OncoEthix Doses First Patient in its Phase I Trial of OTX015, a BET Bromodomain Inhibitor for the Treatment of Hematologic Malignancies

30 January 2013
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precurser Cells in Patients with Active Rheumatoid Arthritis

29 January 2013
Prosensa Achieves Orphan Drug Status on its Entire Duchenne Muscular Dystrophy Portfolio

29 January 2013
4-Antibody AG and the Ludwig Institute

29 January 2013
AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial forHerpes Drug Pritelivir

24 January 2013
Positive results from the BI-505 phase I study in multiple myeloma

22 January 2013
Dezima Pharma in-licenses CETP Inhibitor Program

22 January 2013
Australian Cardiac Monitoring Company Reports Large Reduction in Sepsis Deaths Using Its Non-invasive Heart Monitor

22 January 2013
Synthon Biopharmaceuticals reports positive early results with its second generation HER2-antibody-drug conjugate

17 January 2013
Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its anti-VEGF DARPin MP0112 in Diabetic Macular Edema

17 January 2013
P.L.E.A.S.E.® Laser Device Suitable for Painless Antigen Application

11 January 2013
Mesoblast’s Neofuse Stem Cell Product Shows Positive Results in Phase 2 Lumbar Spinal Fusion Trial

10 January 2013
BioGasol ApS Completes First Carbofrac™ Reactor Sale to Sweetwater Energy

08 January 2013
Thomas Monath and Farshad Guirakhoo Join Hookipa Biotech as Chief Medical Officer and Chief Scientific Officer

08 January 2013
Hookipa Announces Formation of Scientific Advisory Board

07 January 2013
Clinical Network Services (CNS) acquires New Zealand partner BELTAS’ business assets

07 January 2013
Telormedix Granted IND for Phase II in Bladder Cancer

03 January 2013
Prosensa to Present at J.P. Morgan Healthcare Conference

2012

18 December 2012
GE Healthcare and Cellular Dynamics International agree to sublicence for cellular assay patents

18 December 2012
e-Therapeutics provides update on progress of ETS2101 cancer trials

17 December 2012
ZEINCRO Reinforces its Leading Position in Central and South-Eastern Europe

17 December 2012
Karus Therapeutics Announces Collaboration with Babraham Institute to Explore PI3 Kinase Inhibitors in the Treatment of Inflammatory Diseases

13 December 2012
Pre-transplant Umbilical Cord Blood Expansion in Lab Speeds Establishment of New Blood Supply in Patients, Reducing High-risk Time to Recovery

13 December 2012
Henri Termeer joins Prosensa as Strategic Advisor

10 December 2012
Bicycle Therapeutics announces £3.75 million financing for drug discovery

06 December 2012
Two Posters and Two Oral Presentations on NOXXON Compounds at 2012 American Society of Hematology (ASH) Conference

06 December 2012
Sirtex Collaboration with the National Cancer Centre of Singapore

04 December 2012
NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94

03 December 2012
Phagenesis Wins Bionow Award for Healthcare Project of the Year 2012

29 November 2012
Mesoblast Corporate Overview

28 November 2012
FuturaGene and EMBRAPA sign an umbrella Cooperation Framework Agreement

26 November 2012
Apitope Completes Recruitment into its Clinical Trial of ATX-MS-1467 in Multiple Sclerosis

22 November 2012
GE Healthcare’s 2012 Cell Imaging Competition – voting opens to celebrate art, science and discovery

20 November 2012
OGT initiates strategic expansion plans in North America with the opening of New York office and appointment of US sales team

19 November 2012
Marinomed Granted Chinese Patent for Antiviral Polymer

16 November 2012
Veryan receives CE Mark approval for BioMimics 3D™ Stent

15 November 2012
GE Healthcare scientist paired with Cardiff MP to share insights on cell therapy, science and policy-making

14 November 2012
Source BioScience plc Interim Management Statement

13 November 2012
Bacteriophage-based Anti-infective Companies AmpliPhi and Special Phage Services Complete Merger

12 November 2012
BioGasol ApS raises €15 Million in New Equity and Grant Financing led by Unipension, EUDP and Fjord Capital Partners

07 November 2012
Aravis sells German wind farm to EBM

05 November 2012
IXICO and PsiOxus Therapeutics Win Significant Funding from Government-backed Biomedical Catalyst

05 November 2012
International Consortium Awarded €6M to Validate Pre-Eclampsia Early Detection Tests

02 November 2012
Forbion Portfolio Company uniQure receives Approval for Glybera® First Gene Therapy by European Commission

31 October 2012
Vaxxas Recognized as 2012 Janssen AusBiotech Emerging Company of the Year

29 October 2012
Celtic Therapeutics Announces the Appointment of New Partner

25 October 2012
Agenix to Acquire Diagnostic Device Technology from Tyrian Limited

25 October 2012
miReven announces positive preclinical results for miR-7 in head and neck cancer

23 October 2012
Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy

22 October 2012
Scil Proteins Obtains EMA Approval for Commercial Production of Reteplase

18 October 2012
Ampliphi presents encouraging pre-clinical data on the use of phage-based therapies to treat bacterial lung infections

16 October 2012
Phagenesis wins CE mark for Phagenyx™ to treat dysphagia

15 October 2012
BD and Lab21 Collaborate to Develop New Oncology Assays on the BD MAX™ Platform

12 October 2012
Australia’s Benitec Biopharma acquires US-based Tacere Therapeutics Inc and its Phase I/II ready hepatitis C (HCV) program

12 October 2012
Data from Phase I/IIa study of Verona Pharma’s dual PDE 3 and 4 inhibitor RPL554 demonstrated safety and efficacy in healthy subjects and asthmatics

10 October 2012
BAC and GE Healthcare collaboration wins industry award

10 October 2012
LEUKOCARE licenses biomarker cell-free DNA to Trillium Diagnostics

09 October 2012
Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

04 October 2012
Circassia Initiates Phase III Trial for Cat Allergy Treatment

25 September 2012
Brooks Life Science Systems Launch the Plate Auditor™ for Automated Compound Quality Control

24 September 2012
Multiplicom Launches New Genomic and Somatic Mutation Detection Kits

19 September 2012
Prosensa Named a Fierce 15 Biotech Company

14 September 2012
Verona Pharma: Interim Report for the Six Months Ended 30 June 2012

13 September 2012
FuturaGene appoints Dr. Michael May, VP Public Affairs

12 September 2012
Brooks’ Single-Use REMP Tubes Support Optimization of Automated Serum and Plasma storage

12 September 2012
e-Therapeutics Starts Second Phase I Cancer Trial of ETS2101

10 September 2012
AmpliPhi to Combine with Special Phage Services to Create World's Leading Anti-infective Company Focused on Bacteriophage-based Therapies

10 September 2012
Forbion Announces Appointment of Philip Astley-Sparke as Venture Partner

06 September 2012
Karus Therapeutics Secures Series B Financing from a Syndicate of Leading VC Investors

05 September 2012
OGT Forms Scientific Advisory Board

04 September 2012
GE Healthcare launches modular biopharmaceutical factory, KUBio

04 September 2012
Verona Pharma Reports Bronchodilator Data with RPL554 in COPD Patients at the 2012 European Respiratory Society

03 September 2012
New Data on RPL554 in COPD to be Presented at ERS Annual Congress

30 August 2012
Brooks Life Science Systems Announces New Applications for Celigo® Imaging Cytometer

28 August 2012
US Patent Granted for Verona Pharma’s RPL554

27 August 2012
Mireven Receives Further $500K from MRCF

24 August 2012
GE Healthcare launches ÄKTA™ pure, a new modular chromatography system for protein purification

22 August 2012
EBM and ewb Take Over 70-Megawatt Wind Farms

21 August 2012
Allergan and Molecular Partners Enter into Exclusive Alliance

21 August 2012
Source Bioscience: Half Year Report for the Six Months Ended 30 June 2012

09 August 2012
FuturaGene Launches Field Trials in China

01 August 2012
GE Healthcare launches FF High Performance nitrocellulose membranes optimized for diagnostic assay reproducibility

01 August 2012
NICE Publishes Positive Diagnostics Guidance on DySIS Cervical Cancer Screening Product

30 July 2012
FuturaGene Head of R&D Appointed Extraordinary Professor for Forestry and Agricultural Biotechnology

26 July 2012
iBio, Inc. and GE Healthcare Form New Global Alliance

24 July 2012
OGT Awarded €3 Million from Prestigious EU Clinical Research Grants

24 July 2012
Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis

24 July 2012
Trading Update for the Six Months Ended 30 June 2012

23 July 2012
Boehringer Ingelheim and Funxional Therapeutics Announce Acquisition of Funxional’s FX125L and the Somatotaxin Portfolio to Treat Inflammation

23 July 2012
Innovations Invests in £17 Million Funding Round for Portfolio Company, Cell Medica

20 July 2012
Forbion Portfolio Company, uniQure Receives Positive Opinion for Glybera® in Europe from CHMP

17 July 2012
ADC Therapeutics Appoints Former Genmab VP Dr Patrick van Berkel as Senior VP of R&D

12 July 2012
Lab21 Among First to Offer FDA Approved Companion Diagnostic in the US

11 July 2012
NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX A12 for Treatment of Chronic Lymphocytic Leukemia

09 July 2012
Clydesdale Bank £5 million funding to support Lab21 international growth

09 July 2012
Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-term Pre-eclampsia Cases in SCOPE Consortium Study

09 July 2012
Verona Pharma Initiates Dosing in Clinical Trial to Investigate Anti-inflammatory Properties of RPL554

06 July 2012
Cancer Research Technology and ADC Therapeutics Join Forces on Antibody Drug Conjugates

04 July 2012
LEUKOCARE Provides Key Technologies for Tumour Diagnosis in Personalized Medicine Research Project Multi-National Consortium Receives €6 Million EU Grant

02 July 2012
Source BioScience Launches New Illumina MiSeq™ Next Generation DNA Sequencing Service

28 June 2012
Bioxyne reports the results from the Phase IIb study

27 June 2012
Celtic Pharma: Data from New Drug Trial Offers Prospect for Enhanced Quality of Life for Children with Late Stage Brain Tumors

27 June 2012
ProtAffin AG starts Phase 1 study for lead product PA401 in inflammatory lung disease

27 June 2012
Imperial Innovations Group plc – Abingdon Health acquires controlling stake in Forsite Diagnostics

26 June 2012
Lab21 partners with major pharmaceutical company to develop new companion diagnostic assay

22 June 2012
Astex Pharmaceuticals Announces Initiation of the Phase 2 Expansion of the SGI-110 clinical trial in MDS and AML Patients

22 June 2012
Prosensa wins “Emerging Star Award” at the European Mediscience Awards

19 June 2012
Multiplicom’s BRCA MASTR™ Dx test accredited with CE/IVD mark

19 June 2012
NOXXON Initiates Phase IIa of anti-CCL2/MCP-1 Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy

18 June 2012
Imperial Innovations Group plc – Innovations leads $28m funding round for Oxford Immunotec

18 June 2012
PolyTherics granted further patents for TheraPEG™ and GlycoPol™

15 June 2012
OncoEthix In-Licenses OTX015, an anticancer Bromodomain inhibitor from Mitsubishi Tanabe Pharma Corporation

13 June 2012
Astex Pharmaceuticals Earns $5.4 Million Milestone on Phase I Trial Initiation of a FGFR Kinase Inhibitor

13 June 2012
Annual General Meeting Statement

12 June 2012
BGI, GE Healthcare team up on pioneering stem cell science projects

12 June 2012
Polyphor signs MacroFinder® collaboration with Boehringer Ingelheim

12 June 2012
BioInvent and Cancer Research Technology enter Oncology collaboration

11 June 2012
Trial Masters joins ZEINCRO to create specialist CRO in Central- and South-Eastern Europe

11 June 2012
Microtest Diagnostics appoints senior industry executive Kjell Kristiansen as Group Managing Director

08 June 2012
Mesoblast Provides Corporate Strategy For Product Development To Treat Neurologic Conditions

07 June 2012
Multiplicom receives €200,000 grant for novel non-invasive pre-natal test

01 June 2012
Forest Laboratories and Nabriva Therapeutics Sign Agreement

01 June 2012
CEO’s Statement to Annual General Meeting

31 May 2012
Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as Chief Medical Officer

29 May 2012
Pro Bono Bio and PolyTherics progress and expand their relationship for the development of improved blood factors

28 May 2012
Bioxyne On Track To Report Clinical Trial Results In June